| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-05-04 | University of Pennsylvania | R&D collaboration |
R&D agreement | |||
| 2016-05-04 | Audentes Therapeutics (USA - CA) University of Pennsylvania (US - PA) | AT342 | Crigler-Najjar Syndrome | collaboration - research | Rare diseases - Genetic diseases - Hepatic diseases - Liver diseases | Collaboration agreement |
| 2016-05-03 | Orchard Therapeutics (UK) University College London (UK) Great Ormond Street Hospital for Children NHS Foundation Trust (UK) the University of Manchester (UK) the University of California Los Angeles (USA - CA) Boston Children’s Hospital (USA - MA) | gene therapies | R&D |
Rare diseases - Genetic diseases | R&D agreement | |
| 2016-05-03 | Ionis Pharmaceuticals (USA - CA) Kastle Therapeutics (USA - IL) | Kynamro® (mipomersen sodium) | homozygous familial hypercholesterolemia (HoFH) | product acquisition |
Rare diseases - Genetic diseases - Metabolic diseases | Product acquisition |
| 2016-05-03 | RXi Pharmaceuticals (USA - MA) Thera Neuropharma (USA - PA) | self-delivering RNAi (sd-rxRNA®) compounds targeting superoxide dismutase 1 (SOD1) | amyotrophic lateral sclerosis (ALS) | licensing |
Neurodegenerative diseases | Licensing agreement |
| 2016-05-03 | Ipsen (France) Oncodesign (France) | R&D |
Cancer - Oncology | R&D agreement | ||
| 2016-05-02 | Merck KGaA (Germany) | new facility at Martillac (France) | opening of new premises |
Technology - Services | Opening of new premises | |
| 2016-05-02 | Bind Therapeutics (USA - MA) | restructuring |
Cancer - Oncology | Restructuring | ||
| 2016-04-29 | Pfizer (USA - NY) Swedish Orphan Biovitrum (Sobi) (Sweden) | ReFacto AF® (EU)/Xytna® (USA) (moroctocog alfa), Kineret® | treatment and prophylaxis of bleeding in patients with hemophilia A (congenital factor VIII deficiency), Cryopyrin-Associated Periodic Syndromes (CAPS): neonatal-onset multisystem inflammatory disease (NOMID) Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA) Muckle-Wells Syndrome (MWS) Familial Cold Autoinflammatory Syndrome (FCAS) | manufacturing production |
Hematologic diseases - Genetic diseases - Rare diseases | Production agreement |
| 2016-04-29 | Ablynx (Belgium) Novartis (Switlzerland) | R&D |
Milestone | |||
| 2016-04-28 | Shire (UK - USA) | nomination |
Nomination | |||
| 2016-04-28 | Alnylam Therapeutics (USA - MA) | RNAi therapeutics | construction of a production plant |
Construction of a production plant | ||
| 2016-04-27 | Medday (France) | nomination |
Autoimmune diseases - Neurodegenerative diseases - Neurological diseases | Nomination | ||
| 2016-04-26 | Ipsen (France) Probi (Sweden) | Lactobacillus plantarum 299v (LP299V®) | irritable bowel syndrome | licensing commercialisation |
Gastrointestinal diseases - Digestive diseases | Licensing agreement |
| 2016-04-26 | Abivax (France) PCAS (France) | ABX464 | HIV infection | production manufacturing services contract |
Infectious diseases | Services contract |
| 2016-04-26 | Oxford Biomedica (UK) | nomination |
Nomination | |||
| 2016-04-26 | Bionor Pharma (Norway) | resignation |
Infectious diseases | Resignation | ||
| 2016-04-26 | Galena Biopharma (USA - OR) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-04-26 | PTC Therapeutics (USA - NJ) | nomination |
Rare diseases - Genetic diseases | Nomination | ||
| 2016-04-26 | AstraZeneca (UK) Ironwood Pharmaceuticals (USA - MA) | lesinurad | gout | licensing | Inflammatory diseases | Licensing agreement |
